{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:03:25Z","timestamp":1784898205633,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00120-026-02865-w","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:00:27Z","timestamp":1782471627000},"page":"842-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vorbeugen statt nachschieben \u2013\u00a0Fr\u00fcherkennung, Lebensstilberatung und Prostatavorsorge\u00a02.0\u00a0\u2013 Wandel der Urologie zum Gesundheitscoach","Prevention instead of remediation\u2014screening, lifestyle factors, and prostate care\u00a02.0\u2014transition of urology to healthcare coach"],"prefix":"10.1007","volume":"65","author":[{"given":"Fabian","family":"Falkenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouvier","family":"Al-Monajjed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Reimold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid V.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2865_CR1","volume-title":"Edn. presented at the EAU Annual Congress London 2026","author":"EAU Guidelines","year":"2026","unstructured":"EAU Guidelines (2026) Edn. presented at the EAU Annual Congress London 2026 ISBN 978-94-92671-32\u20115."},{"key":"2865_CR2","unstructured":"National Comprehensive Cancer Network, Inc (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.1.2025."},{"key":"2865_CR3","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2025) S3-Leitlinie Prostatakarzinom, Langversion 8.1, 2025, AWMF-Registernummer: 043-022OL."},{"key":"2865_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.3579","author":"A Kinnaird","year":"2025","unstructured":"Kinnaird\u00a0A, Luger\u00a0F, Cash\u00a0H, Ghai\u00a0S, Urdaneta-Salegui\u00a0LF, Pavlovich\u00a0CP et\u00a0al (2025) Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMAe253579. https:\/\/doi.org\/10.1001\/jama.2025.3579","journal-title":"JAMA"},{"key":"2865_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/JU.0000000000004995","volume":"215","author":"DW Lin","year":"2026","unstructured":"Lin\u00a0DW, Carlsson\u00a0S, Filson\u00a0CP, Kim\u00a0SK, Kirkby\u00a0E, Konety\u00a0BR et\u00a0al (2026) Updates to Early Detection of Prostate Cancer: AUA\/SUO Guideline (2026). J\u00a0Urol 215:491\u2013501. https:\/\/doi.org\/10.1097\/JU.0000000000004995","journal-title":"J Urol"},{"key":"2865_CR6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.urology.2012.08.004","volume":"80","author":"A Kayikci","year":"2012","unstructured":"Kayikci\u00a0A, Cam\u00a0K, Kacagan\u00a0C, Tekin\u00a0A, Ankarali\u00a0H (2012) Free prostate-specific antigen is a better tool than total prostate-specific antigen at predicting prostate volume in patients with lower urinary tract symptoms. Urol Video J 80:1088\u20131092. https:\/\/doi.org\/10.1016\/j.urology.2012.08.004","journal-title":"Urology"},{"key":"2865_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000020258","volume":"38","author":"J Morote","year":"2000","unstructured":"Morote\u00a0J, Encabo\u00a0G, L\u00f3pez\u00a0M, de Torres\u00a0IM (2000) Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol 38:91\u201395. https:\/\/doi.org\/10.1159\/000020258","journal-title":"Eur Urol"},{"key":"2865_CR8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.urology.2004.08.049","volume":"64","author":"B Djavan","year":"2004","unstructured":"Djavan\u00a0B, Fong\u00a0YK, Harik\u00a0M, Milani\u00a0S, Reissigl\u00a0A, Chaudry\u00a0A et\u00a0al (2004) Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urol Video J 64:1144\u20131148. https:\/\/doi.org\/10.1016\/j.urology.2004.08.049","journal-title":"Urology"},{"key":"2865_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/s0090-4295(99)00232-0","volume":"54","author":"CG Roehrborn","year":"1999","unstructured":"Roehrborn\u00a0CG, Boyle\u00a0P, Bergner\u00a0D, Gray\u00a0T, Gittelman\u00a0M, Shown\u00a0T, PLESS Study Group et\u00a0al (1999) Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 54:662\u2013669. https:\/\/doi.org\/10.1016\/s0090-4295(99)00232-0","journal-title":"Urology"},{"key":"2865_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-5347(05)67962-1","volume":"163","author":"CG Roehrborn","year":"2000","unstructured":"Roehrborn\u00a0CG, McConnell\u00a0J, Bonilla\u00a0J, Rosenblatt\u00a0S, Hudson\u00a0PB, Malek\u00a0GH et\u00a0al (2000) Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J\u00a0Urol 163:13\u201320","journal-title":"J Urol"},{"key":"2865_CR11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell\u00a0JD, Roehrborn\u00a0CG, Bautista\u00a0OM, Andriole\u00a0GL, Dixon\u00a0CM, Kusek\u00a0JW et\u00a0al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387\u20132398. https:\/\/doi.org\/10.1056\/NEJMoa030656","journal-title":"N Engl J Med"},{"key":"2865_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1464-410X.2006.06110.x","volume":"97","author":"CG Roehrborn","year":"2006","unstructured":"Roehrborn\u00a0CG (2006) Alfuzosin 10\u202fmg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a\u00a02-year placebo-controlled study. BJU Int 97:734\u2013741. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06110.x","journal-title":"BJU Int"},{"key":"2865_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan\u00a0KB (2016) The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am 43:289\u2013297. https:\/\/doi.org\/10.1016\/j.ucl.2016.04.001","journal-title":"Urol Clin North Am"},{"key":"2865_CR14","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1111\/jsm.12266","volume":"10","author":"G Rastrelli","year":"2013","unstructured":"Rastrelli\u00a0G, Corona\u00a0G, Vignozzi\u00a0L, Maseroli\u00a0E, Silverii\u00a0A, Monami\u00a0M et\u00a0al (2013) Serum PSA as a predictor of testosterone deficiency. J\u00a0Sex Med 10:2518\u20132528. https:\/\/doi.org\/10.1111\/jsm.12266","journal-title":"J Sex Med"},{"key":"2865_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/1008-682X.148067","volume":"17","author":"A Morgentaler","year":"2015","unstructured":"Morgentaler\u00a0A, Conners\u00a0WP (2015) Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations. Asian J Androl 17:206\u2013211. https:\/\/doi.org\/10.4103\/1008-682X.148067","journal-title":"Asian J Androl"},{"key":"2865_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","volume":"69","author":"AL Kaplan","year":"2016","unstructured":"Kaplan\u00a0AL, Hu\u00a0JC, Morgentaler\u00a0A, Mulhall\u00a0JP, Schulman\u00a0CC, Montorsi\u00a0F (2016) Testosterone Therapy in Men With Prostate Cancer. Eur Urol Oncol 69:894\u2013903. https:\/\/doi.org\/10.1016\/j.eururo.2015.12.005","journal-title":"Eur Urol"},{"key":"2865_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","volume":"55","author":"A Morgentaler","year":"2009","unstructured":"Morgentaler\u00a0A, Traish\u00a0AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol Oncol 55:310\u2013320. https:\/\/doi.org\/10.1016\/j.eururo.2008.09.024","journal-title":"Eur Urol"},{"key":"2865_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1097\/01.ju.0000158040.33531.e7","volume":"173","author":"G Isom-Batz","year":"2005","unstructured":"Isom-Batz\u00a0G, Bianco\u00a0FJ, Kattan\u00a0MW, Mulhall\u00a0JP, Lilja\u00a0H, Eastham\u00a0JA (2005) Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J\u00a0Urol 173:1935\u20131937. https:\/\/doi.org\/10.1097\/01.ju.0000158040.33531.e7","journal-title":"J Urol"},{"key":"2865_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jsxm.2022.01.003","volume":"19","author":"JM Flores","year":"2022","unstructured":"Flores\u00a0JM, Bernie\u00a0HL, Miranda\u00a0E, Nascimento\u00a0B, Schofield\u00a0E, Benfante\u00a0N et\u00a0al (2022) The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer. J\u00a0Sex Med 19:471\u2013478. https:\/\/doi.org\/10.1016\/j.jsxm.2022.01.003","journal-title":"J Sex Med"},{"key":"2865_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/iju.13042","volume":"23","author":"WS Choi","year":"2016","unstructured":"Choi\u00a0WS, Heo\u00a0NJ, Paick\u00a0JS, Son\u00a0H (2016) Prostate-specific antigen lowering effect of metabolic syndrome is influenced by prostate volume. Int J Urol 23:299\u2013304. https:\/\/doi.org\/10.1111\/iju.13042","journal-title":"Int J Urol"},{"key":"2865_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.ijir.3901397","volume":"18","author":"AD Seftel","year":"2006","unstructured":"Seftel\u00a0AD (2006) Male hypogonadism. Part\u00a0I:\u00a0Epidemiology of hypogonadism. Int J Impot Res 18:115\u2013120. https:\/\/doi.org\/10.1038\/sj.ijir.3901397","journal-title":"Int J Impot Res"},{"key":"2865_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.7326\/M23-2781","volume":"177","author":"BB Yeap","year":"2024","unstructured":"Yeap\u00a0BB, Marriott\u00a0RJ, Dwivedi\u00a0G, Adams\u00a0RJ, Antonio\u00a0L, Ballantyne\u00a0CM et\u00a0al (2024) Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses. Ann Intern Med 177:768\u2013781. https:\/\/doi.org\/10.7326\/M23-2781","journal-title":"Ann Intern Med"},{"key":"2865_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2164\/jandrol.108.005751","volume":"30","author":"AM Traish","year":"2009","unstructured":"Traish\u00a0AM, Saad\u00a0F, Guay\u00a0A (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J\u00a0Androl 30:23\u201332. https:\/\/doi.org\/10.2164\/jandrol.108.005751","journal-title":"J Androl"},{"key":"2865_CR24","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan\u00a0V, Rannikko\u00a0AS, Borghi\u00a0M, Panebianco\u00a0V, Mynderse\u00a0LA, Vaarala\u00a0MH et\u00a0al (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"2865_CR25","doi-asserted-by":"publisher","first-page":"S761","DOI":"10.1016\/S0302-2838(23)00580-8","volume":"83","author":"A Ng","year":"2023","unstructured":"Ng\u00a0A, Asif\u00a0A, Nathan\u00a0A, Khetrapal\u00a0P, Chan\u00a0VWS, Rossiter\u00a0M et\u00a0al (2023) Comparison of biparametric and multiparametric magnetic resonance imaging for prostate cancer detection: an 8\u2011month update on the PRIME Study (NCT04571840). European Urology 83:S761\u2013S762. https:\/\/doi.org\/10.1016\/S0302-2838(23)00580-8","journal-title":"European Urology"},{"key":"2865_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.2214\/AJR.14.13602","volume":"205","author":"NF Wasserman","year":"2015","unstructured":"Wasserman\u00a0NF, Spilseth\u00a0B, Golzarian\u00a0J, Metzger\u00a0GJ (2015) Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies. AJR Am J Roentgenol 205:564\u2013571. https:\/\/doi.org\/10.2214\/AJR.14.13602","journal-title":"AJR Am J Roentgenol"},{"key":"2865_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.urology.2022.09.007","volume":"171","author":"S Choe","year":"2023","unstructured":"Choe\u00a0S, Patel\u00a0HD, Lanzotti\u00a0N, Okabe\u00a0Y, Rac\u00a0G, Shea\u00a0SM et\u00a0al (2023) MRI vs Transrectal Ultrasound to Estimate Prostate Volume and PSAD: Impact on Prostate Cancer Detection. Urol Video J 171:172\u2013178. https:\/\/doi.org\/10.1016\/j.urology.2022.09.007","journal-title":"Urology"},{"key":"2865_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.urology.2023.04.012","volume":"177","author":"J Yang","year":"2023","unstructured":"Yang\u00a0J, Ma\u00a0Q, Liu\u00a0J, Zu\u00a0H, Dong\u00a0S, Liu\u00a0Y et\u00a0al (2023) Multiparametric Magnetic Resonance Imaging With Comprehensive Assessment of Prostate Volume, Morphology, and Composition Better Reflects the Correlation With International Prostate Symptom Score. Urol Video J 177:134\u2013141. https:\/\/doi.org\/10.1016\/j.urology.2023.04.012","journal-title":"Urology"},{"key":"2865_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s42155-023-00357-y","volume":"6","author":"M Boschheidgen","year":"2023","unstructured":"Boschheidgen\u00a0M, Al-Monajjed\u00a0R, Minko\u00a0P, Jannusch\u00a0K, Ullrich\u00a0T, Radke\u00a0KL et\u00a0al (2023) Influence of benign prostatic hyperplasia patterns detected with MRI on the clinical outcome after prostatic artery embolization. CVIR Endovasc 6:9. https:\/\/doi.org\/10.1186\/s42155-023-00357-y","journal-title":"CVIR Endovasc"},{"key":"2865_CR30","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1007\/s00261-024-04233-8","volume":"49","author":"JH Park","year":"2024","unstructured":"Park\u00a0JH, Yoon\u00a0J, Park\u00a0I, Kang\u00a0JG, Lee\u00a0J, Kim\u00a0JH et\u00a0al (2024) Peripheral zone thickness in preoperative MRI is predictive of Trifecta achievement after Holmium laser enucleation of the prostate (HoLEP). Abdom Radiol 49:2358\u20132367. https:\/\/doi.org\/10.1007\/s00261-024-04233-8","journal-title":"Abdom Radiol"},{"key":"2865_CR31","doi-asserted-by":"crossref","unstructured":"Watanabe K, Otsuka A, Kitagawa Y, Sano A, Sato R, Matsushita Y, et\u00a0al. Preoperative factors predicting poor therapeutic efficacy of holmium laser enucleation of the prostate in patients with benign prostatic hyperplasia. Low Urin Tract Symptoms 2024;16:e12530. https:\/\/doi.org\/10.1111\/luts.12530.","DOI":"10.1111\/luts.12530"},{"key":"2865_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2024.106790","volume":"82","author":"ZT Ruan","year":"2025","unstructured":"Ruan\u00a0ZT, Li\u00a0XD, Lin\u00a0XD, Ye\u00a0XJ, Chen\u00a0JY, Chen\u00a0YH et\u00a0al (2025) Can bladder neck thickness on magnetic resonance imaging (MRI) predict early outcomes after anatomic enucleation of the prostate (AEEP) in benign prostatic hyperplasia patients with small-volume prostate? Clin Radiol 82:106790. https:\/\/doi.org\/10.1016\/j.crad.2024.106790","journal-title":"Clin Radiol"},{"key":"2865_CR33","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00345-014-1241-5","volume":"32","author":"I Soljanik","year":"2014","unstructured":"Soljanik\u00a0I, Bauer\u00a0RM, Becker\u00a0AJ, Stief\u00a0CG, Gozzi\u00a0C, Solyanik\u00a0O et\u00a0al (2014) Is a\u00a0wider angle of the membranous urethra associated with incontinence after radical prostatectomy? World J Urol 32:1375\u20131383. https:\/\/doi.org\/10.1007\/s00345-014-1241-5","journal-title":"World J Urol"},{"key":"2865_CR34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.euf.2022.01.015","volume":"8","author":"MC van Dijk-de Haan","year":"2022","unstructured":"van Dijk-de Haan\u00a0MC, Boellaard\u00a0TN, Tissier\u00a0R, Heijmink\u00a0SWTPJ, van Leeuwen\u00a0PJ, van der Poel\u00a0HG et\u00a0al (2022) Value of Different Magnetic Resonance Imaging-based Measurements of Anatomical Structures on Preoperative Prostate Imaging in Predicting Urinary Continence After Radical Prostatectomy in Men with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 8:1211\u20131225. https:\/\/doi.org\/10.1016\/j.euf.2022.01.015","journal-title":"Eur Urol Focus"},{"key":"2865_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2016.06.023","volume":"71","author":"SF Mungovan","year":"2017","unstructured":"Mungovan\u00a0SF, Sandhu\u00a0JS, Akin\u00a0O, Smart\u00a0NA, Graham\u00a0PL, Patel\u00a0MI (2017) Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis. Eur Urol Oncol 71:368\u2013378. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.023","journal-title":"Eur Urol"},{"key":"2865_CR36","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s11255-021-02809-7","volume":"53","author":"M Wenzel","year":"2021","unstructured":"Wenzel\u00a0M, Preisser\u00a0F, Mueller\u00a0M, Theissen\u00a0LH, Welte\u00a0MN, Hoeh\u00a0B et\u00a0al (2021) Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy. Int Urol Nephrol 53:1297\u20131303. https:\/\/doi.org\/10.1007\/s11255-021-02809-7","journal-title":"Int Urol Nephrol"},{"key":"2865_CR37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.eururo.2008.08.057","volume":"55","author":"P Paparel","year":"2009","unstructured":"Paparel\u00a0P, Akin\u00a0O, Sandhu\u00a0JS, Otero\u00a0JR, Serio\u00a0AM, Scardino\u00a0PT et\u00a0al (2009) Recovery of urinary continence after radical prostatectomy: association with urethral length and urethral fibrosis measured by preoperative and postoperative endorectal magnetic resonance imaging. Eur Urol Oncol 55:629\u2013637. https:\/\/doi.org\/10.1016\/j.eururo.2008.08.057","journal-title":"Eur Urol"},{"key":"2865_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/iju.14322","volume":"27","author":"H Ueki","year":"2020","unstructured":"Ueki\u00a0H, Takahashi\u00a0K, Yasufuku\u00a0T, Yuen\u00a0K, Yamashita\u00a0M (2020) Is the membranous urethral length related to postoperative urinary incontinence after holmium laser enucleation of the prostate? Int J Urol 27:893\u2013898. https:\/\/doi.org\/10.1111\/iju.14322","journal-title":"Int J Urol"},{"key":"2865_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.eururo.2011.07.007","volume":"60","author":"Y Liu","year":"2011","unstructured":"Liu\u00a0Y, Hu\u00a0F, Li\u00a0D, Wang\u00a0F, Zhu\u00a0L, Chen\u00a0W et\u00a0al (2011) Does Physical Activity Reduce the Risk of Prostate Cancer? A Systematic Review and Meta-analysis. Eur Urol Oncol 60:1029\u20131044. https:\/\/doi.org\/10.1016\/j.eururo.2011.07.007","journal-title":"European Urology"},{"key":"2865_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1249\/mss.0000000000001454","volume":"50","author":"DA Galv\u00e3o","year":"2018","unstructured":"Galv\u00e3o\u00a0DA, Taaffe\u00a0DR, Spry\u00a0N, Cormie\u00a0P, Joseph\u00a0D, Chambers\u00a0SK et\u00a0al (2018) Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases. Med Sci Sports Exerc 50:393\u2013399. https:\/\/doi.org\/10.1249\/mss.0000000000001454","journal-title":"Med Sci Sports Exerc"},{"key":"2865_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.physio.2019.01.002","volume":"105","author":"C Myers","year":"2019","unstructured":"Myers\u00a0C, Smith\u00a0M (2019) Pelvic floor muscle training improves erectile dysfunction and premature ejaculation: a\u00a0systematic review. Physiotherapy 105:235\u2013243. https:\/\/doi.org\/10.1016\/j.physio.2019.01.002","journal-title":"Physiotherapy"},{"key":"2865_CR42","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400290","volume":"4","author":"C Gratzke","year":"2025","unstructured":"Gratzke\u00a0C, Sch\u00f6nburg\u00a0S, Eger\u00a0S, Raude\u00a0K, Grabbert\u00a0M, Astheimer\u00a0S et\u00a0al (2025) A Randomized Trial of an App-Based Therapeutic for Lower Urinary Tract Symptoms. NEJM Evid 4:EVIDoa2400290. https:\/\/doi.org\/10.1056\/EVIDoa2400290","journal-title":"NEJM Evid"},{"key":"2865_CR43","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.euf.2024.05.020","volume":"10","author":"S Kliesch","year":"2024","unstructured":"Kliesch\u00a0S, Cremers\u00a0JF, Krallmann\u00a0C, Epplen\u00a0R, Scheffer\u00a0B, Schubert\u00a0T et\u00a0al (2024) App-based Therapy of Erectile Dysfunction Using a Digital Health Application (EDDIG Study): A Randomized, Single-blind, Controlled Trial. Eur Urol Oncol 10:1003\u20131010. https:\/\/doi.org\/10.1016\/j.euf.2024.05.020","journal-title":"Eur Urol Focus"},{"key":"2865_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren\u00a0O, Pekala\u00a0KR, Matsoukas\u00a0K, Fainberg\u00a0J, Mungovan\u00a0SF, Bratt\u00a0O et\u00a0al (2023) 2022 Update on Prostate Cancer Epidemiology and Risk Factors\u2011A Systematic Review. Eur Urol Oncol 84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","journal-title":"Eur Urol"},{"key":"2865_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.eururo.2025.07.017","volume":"88","author":"PH Lin","year":"2025","unstructured":"Lin\u00a0PH, Burwell\u00a0AD, Giovannucci\u00a0EL, Loeb\u00a0S, Chan\u00a0JM, Tuttle\u00a0B et\u00a0al (2025) Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials. Eur Urol Oncol 88:571\u2013588. https:\/\/doi.org\/10.1016\/j.eururo.2025.07.017","journal-title":"Eur Urol"},{"key":"2865_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41585-024-00939-y","volume":"22","author":"S Loeb","year":"2025","unstructured":"Loeb\u00a0S, Borin\u00a0JF, Venigalla\u00a0G, Narasimman\u00a0M, Gupta\u00a0N, Cole\u00a0AP et\u00a0al (2025) Plant-based diets and urological health. Nat Rev Urol 22:199\u2013207. https:\/\/doi.org\/10.1038\/s41585-024-00939-y","journal-title":"Nat Rev Urol"},{"key":"2865_CR47","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/cncr.35172","volume":"130","author":"S Loeb","year":"2024","unstructured":"Loeb\u00a0S, Hua\u00a0Q, Bauer\u00a0SR, Kenfield\u00a0SA, Morgans\u00a0AK, Chan\u00a0JM et\u00a0al (2024) Plant-based diet associated with better quality of life in prostate cancer survivors. Cancer Cytopathol 130:1618\u20131628. https:\/\/doi.org\/10.1002\/cncr.35172","journal-title":"Cancer"},{"key":"2865_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000001260","volume":"94","author":"P Chen","year":"2015","unstructured":"Chen\u00a0P, Zhang\u00a0W, Wang\u00a0X, Zhao\u00a0K, Negi\u00a0DS, Zhuo\u00a0L et\u00a0al (2015) Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 94:e1260. https:\/\/doi.org\/10.1097\/md.0000000000001260","journal-title":"Medicine (Baltimore)"},{"key":"2865_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1251895","volume":"13","author":"D ElKhalifa","year":"2023","unstructured":"ElKhalifa\u00a0D, Al-Ziftawi\u00a0N, Awaisu\u00a0A, Alali\u00a0F, Khalil\u00a0A (2023) Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials. Front Oncol 13:1251895. https:\/\/doi.org\/10.3389\/fonc.2023.1251895","journal-title":"Frontiers in Oncology"},{"key":"2865_CR50","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1158\/1078-0432.Ccr-05-2290","volume":"12","author":"AJ Pantuck","year":"2006","unstructured":"Pantuck\u00a0AJ, Leppert\u00a0JT, Zomorodian\u00a0N, Aronson\u00a0W, Hong\u00a0J, Barnard\u00a0RJ et\u00a0al (2006) Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12:4018\u20134026. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-2290","journal-title":"Clin Cancer Res"},{"key":"2865_CR51","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1001\/jama.2015.14905","volume":"314","author":"A Jemal","year":"2015","unstructured":"Jemal\u00a0A, Fedewa\u00a0SA, Ma\u00a0J, Siegel\u00a0R, Lin\u00a0CC, Brawley\u00a0O et\u00a0al (2015) Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA 314:2054\u20132061. https:\/\/doi.org\/10.1001\/jama.2015.14905","journal-title":"JAMA"},{"key":"2865_CR52","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/cncr.32604","volume":"126","author":"SS Butler","year":"2020","unstructured":"Butler\u00a0SS, Muralidhar\u00a0V, Zhao\u00a0SG, Sanford\u00a0NN, Franco\u00a0I, Fullerton\u00a0ZH et\u00a0al (2020) Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer Cytopathol 126:717\u2013724. https:\/\/doi.org\/10.1002\/cncr.32604","journal-title":"Cancer"},{"key":"2865_CR53","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.2015.7273","volume":"314","author":"JD Sammon","year":"2015","unstructured":"Sammon\u00a0JD, Abdollah\u00a0F, Choueiri\u00a0TK, Kantoff\u00a0PW, Nguyen\u00a0PL, Menon\u00a0M et\u00a0al (2015) Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA 314:2077\u20132079. https:\/\/doi.org\/10.1001\/jama.2015.7273","journal-title":"JAMA"},{"key":"2865_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrurol.2016.251","volume":"14","author":"K Fleshner","year":"2017","unstructured":"Fleshner\u00a0K, Carlsson\u00a0SV, Roobol\u00a0MJ (2017) The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol 14:26\u201337. https:\/\/doi.org\/10.1038\/nrurol.2016.251","journal-title":"Nat Rev Urol"},{"key":"2865_CR55","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.eururo.2018.06.022","volume":"74","author":"H Gr\u00f6nberg","year":"2018","unstructured":"Gr\u00f6nberg\u00a0H, Eklund\u00a0M, Picker\u00a0W, Aly\u00a0M, J\u00e4derling\u00a0F, Adolfsson\u00a0J et\u00a0al (2018) Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol Oncol 74:722\u2013728. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.022","journal-title":"Eur Urol"},{"key":"2865_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.eururo.2025.12.002","volume":"89","author":"SV Carlsson","year":"2026","unstructured":"Carlsson\u00a0SV, Krilaviciute\u00a0A, Al-Monajjed\u00a0R, Seibold\u00a0P, Kuczyk\u00a0M, Gschwend\u00a0JE et\u00a0al (2026) Risk-adapted Prostate Cancer Screening Achieves Mammography-like Benefits: Evidence and Implications for Europe. Eur Urol Oncol 89:193\u2013195. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.002","journal-title":"Eur Urol"},{"key":"2865_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.urology.2022.08.014","volume":"170","author":"C Andolfi","year":"2022","unstructured":"Andolfi\u00a0C, Vickers\u00a0AJ, Cooperberg\u00a0MR, Carroll\u00a0PR, Cowan\u00a0JE, Paner\u00a0GP et\u00a0al (2022) Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urol Video J 170:154\u2013160. https:\/\/doi.org\/10.1016\/j.urology.2022.08.014","journal-title":"Urology"},{"key":"2865_CR58","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/s1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re\u00a0O, Puech\u00a0P, Renard-Penna\u00a0R, Claudon\u00a0M, Roy\u00a0C, M\u00e8ge-Lechevallier\u00a0F et\u00a0al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100\u2013109. https:\/\/doi.org\/10.1016\/s1470-2045(18)30569-2","journal-title":"Lancet Oncol"},{"key":"2865_CR59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen\u00a0NJ, Omer\u00a0A, Harriss\u00a0E, Davies\u00a0L, Kasivisvanathan\u00a0V, Punwani\u00a0S et\u00a0al (2020) Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. Eur Urol Oncol 78:402\u2013414. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.048","journal-title":"Eur Urol"},{"key":"2865_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clgc.2022.04.001","volume":"20","author":"AG Wibmer","year":"2022","unstructured":"Wibmer\u00a0AG, Lefkowitz\u00a0RA, Lakhman\u00a0Y, Chaim\u00a0J, Nikolovski\u00a0I, Sala\u00a0E et\u00a0al (2022) MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy. Clin Genitourin Cancer 20:319\u2013325. https:\/\/doi.org\/10.1016\/j.clgc.2022.04.001","journal-title":"Clin Genitourin Cancer"},{"key":"2865_CR61","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny\u00a0C, Kroiss\u00a0AS, Decristoforo\u00a0C, Fritz\u00a0J, von Guggenberg\u00a0E, Kendler\u00a0D et\u00a0al (2017) (68)Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. EJNMMI Rep 44:941\u2013949. https:\/\/doi.org\/10.1007\/s00259-017-3631-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2865_CR62","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2967\/jnumed.124.268901","volume":"66","author":"DC Chen","year":"2025","unstructured":"Chen\u00a0DC, Buteau\u00a0JP, Emmett\u00a0L, Alipour\u00a0R, de Galiza Barbosa\u00a0F, Roberts\u00a0MJ et\u00a0al (2025) Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET\/CT in the proPSMA Study. J\u00a0Nucl Med 66:713\u2013718. https:\/\/doi.org\/10.2967\/jnumed.124.268901","journal-title":"J Nucl Med"},{"key":"2865_CR63","unstructured":"Impact of [68Ga]Ga-PSMA-11 PET\/CT in the diagnosis of prostate cancer in men with equivocal or non-suspicious findings on multiparametric MRI (PRIMARY2): a\u00a0multi-centre, phase\u00a0III, randomised trial by Buteau J.P., Moon D., Fahey M.T., Roberts M.J., Ayati N., Papa N., Murphy D., Kasivisvanathan V., Du Y.T., Hutton A.C., Jack G., Lee S.F., Lee S.T., Leslie S., Levy S.M., Mitchell C., Morigi J.J., Nguyen A., Patel M.I., Pattison D.A., Yaxley J., Thompson J., Hofman M.S., Emmett L. is presented at EAU26 on Friday 13\u00a0March 2026. n.\u202fd."},{"key":"2865_CR64","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/JU.0000000000004437","volume":"213","author":"A Lazarovich","year":"2025","unstructured":"Lazarovich\u00a0A, Vigneswaran\u00a0H, Palsdottir\u00a0T, Eklund\u00a0M, Discacciati\u00a0A, Nordstr\u00f6m\u00a0T et\u00a0al (2025) A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J\u00a0Urol 213:590\u2013599. https:\/\/doi.org\/10.1097\/JU.0000000000004437","journal-title":"J Urol"},{"key":"2865_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","volume":"68","author":"T Nordstr\u00f6m","year":"2015","unstructured":"Nordstr\u00f6m\u00a0T, Vickers\u00a0A, Assel\u00a0M, Lilja\u00a0H, Gr\u00f6nberg\u00a0H, Eklund\u00a0M (2015) Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol Oncol 68:139\u2013146. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.010","journal-title":"Eur Urol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02865-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:19:32Z","timestamp":1784895572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02865-w"}},"subtitle":["Holistischer Ansatz an die Prostatagesundheit","Holistic approach to prostate health"],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2865"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02865-w","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.V.\u00a0Carlsson hat Vortragshonorare und Reisekostenerstattungen von Ipsen, Astellas und Bayer erhalten und war als wissenschaftliche Beraterin f\u00fcr Prostatype Genomics t\u00e4tig, ohne Bezug zu dieser Arbeit. F.\u00a0Falkenbach hat Reisekostenerstattungen durch Focal Healthcare erhalten. R.\u00a0Al-Monajjed, P.\u00a0Reimold, und J.\u00a0Huber geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}